Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue GLP-1 Prior Auth Coverage Update | Op…
    Ask Trek AI about this page
    CurrentFlorida BluePolicy N/A

    GLP-1 prior authorization for commercial plans

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Florida Blue commercial plan coverage and prior authorization requirements for GLP-1 medications used to treat type 2 diabetes, and lists preferred and non-covered GLP-1 products. Applies to providers submitting pharmacy prior authorization requests for affected members.

    Policy Summary
    PayerFlorida Blue
    PolicyGLP-1 prior authorization for commercial plans
    Policy CodePolicy N/A
    Change TypeAdded prior authorization requirement
    Effective DateApr 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests to Prime Therapeutics via CoverMyMeds with documentation of type 2 diabetes and prior trial/failure of metformin or insulin.
    SourceLink
    POLICY UPDATE CHANGES

    Effective April 1, 2025, Florida Blue requires prior authorization on file for members on prescribed GLP-1 therapy under commercial plans.

    Type 2 diabetes onlyIndication covered
    3 listedPreferred GLP-1 agents

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Denied / excluded
    Weight-loss requests
    Prime Therapeutics / CoverMyMedsSubmission pathway

    Coverage Criteria for GLP-1 Agents

    Initial authorization criteria

    Covered when ALL of the following are met

    Indication: Prescribed for treatment of type 2 diabetesclinical documentation of type 2 diabetes required

    Florida Blue commercial plans only cover GLP-1 drugs for type 2 diabetes; requests lacking documentation will be denied

    Prior therapy: Documentation of trial and failure of metformin, metformin combination drugs, or insulintrial and failure evidenced in submitted records

    Providers must submit documentation of trial and failure to demonstrate medical necessity

    Authorization submission: Prior authorization submitted to Prime Therapeutics via CoverMyMeds with all required informationcomplete request submitted

    Respond promptly to requests for additional information; urgent inquiries require response within 48 hours

    Medications prescribed for weight management, including GLP‑1 products marketed for weight loss such as Wegovy, Zepbound, and Saxenda, are excluded from coverage under Florida Blue commercial plans. Authorization requests submitted for these weight‑loss indications will be denied and members are responsible for payment. Trulicity is also listed as not covered for this drug class.

    Use of GLP‑1 receptor agonists for non–type 2 diabetes indications (for example, weight loss or weight‑management therapy) is considered not covered / medically unnecessary under Florida Blue commercial plans; requests for these indications will be denied.

    Initial Therapy Criteria

    Initial therapy criteria

    Initial approval requires documented prior therapy and diagnosis.

    Diagnosis: Clinical documentation of type 2 diabetes requireddocumented diagnosis present in submitted records

    Authorization requests will be denied if the patient is not a type 2 diabetic or lacks clinical documentation

    Prior medication trial: Trial and failure of metformin, metformin combination drugs, or insulindocumented trial and failure in medical records

    Required prior to GLP-1 approval

    Continuation Therapy Requirements

    Continuation therapy requirement

    Members currently on a prescribed GLP-1 therapy will be required to have a prior authorization on file starting April 1, 2025.

    Existing therapy: Existing members on GLP-1 therapy must have prior authorization on file to continue coverageprior authorization obtained by provider

    Operational requirement effective date April 1, 2025

    Provider Actions and Prior Authorization Instructions

    Prior Authorization

    Prior authorization required for GLP-1 (effective 4/1/2025)

    Prior authorization must be obtained for GLP-1 medications for members with Florida Blue commercial plans beginning April 1, 2025. Submit the prior authorization request to Prime Therapeutics via CoverMyMeds and include all required information in a single complete submission to avoid processing delays.

    • Operational start date: April 1, 2025
    • Submission pathway: Prime Therapeutics via CoverMyMeds
    • Submit one complete prior authorization request (do not submit duplicates)
    Step Therapy

    Document prior trial and failure of metformin or insulin

    Providers must document a prior trial and failure of metformin, metformin combination drugs, or insulin before a GLP-1 will be approved.

    • Document trial and clinical failure of metformin, other metformin combination drugs, or insulin in the submitted records

    Coding and Submission Pathway

    Submission pathwaymixed
    No codes listed
    Response time and quick-reference
    Urgent inquiry response time48 hours to respond to inquiries for urgent pharmacy requests to Prime Therapeutics (CoverMyMeds)
    Standard responsiveness expectationRespond as soon as possible to requests for additional information to avoid delays or denials
    Single submission requirementSubmit a prior authorization request one time only with all required information to prevent processing delays
    Consequence of no/late responseIf urgent inquiries are not answered within 48 hours, the decision may be made based on available information and could result in denial
    Submission channelSend prior authorization requests to Prime Therapeutics via CoverMyMeds

    Definitions and Exclusions

    Weight‑loss GLP-1 exclusion (examples & scope)
    Coverage stanceGLP-1 drugs used for weight loss are excluded from coverage under Florida Blue commercial plans
    Example excluded productsWegovy, Zepbound, Saxenda (weight-loss GLP-1 products) — authorization requests will be denied
    Other non-covered drugTrulicity is listed as not covered for this class
    Member payment responsibilityRequests for excluded weight-loss medications will be denied and patients will have to pay out of pocket
    ApplicabilityApplies to Florida Blue commercial plans including BlueChoice, BlueOptions, BlueSelect, BlueCare, myBlue, SimplyBlue, and Truli for Health

    Step Therapy Requirements

    StepRequirementFailure criteria
    1Documented trial of metformin, a metformin combination product, or insulin prior to initiation of a GLP-1 agentMedical record documentation showing trial and failure (insufficient response, intolerance, or contraindication) of metformin, metformin combination drug, or insulin

    Background

    GLP‑1 receptor agonists are indicated for glycemic control in type 2 diabetes. Florida Blue limits coverage of GLP‑1 agents to FDA‑indicated use for type 2 diabetes and requires prior authorization for covered uses. Medications used specifically for weight management are outside the scope of coverage for commercial plans and will be denied; providers should direct members to available wellness and weight‑management programs offered by Florida Blue as an alternative resource.

    Policy Summary
    PayerFlorida Blue
    PolicyGLP-1 prior authorization for commercial plans
    Policy CodePolicy N/A
    Change TypeAdded prior authorization requirement
    Effective DateApr 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests to Prime Therapeutics via CoverMyMeds with documentation of type 2 diabetes and prior trial/failure of metformin or insulin.
    SourceLink
    On This Page
    Coverage Criteria for GLP-1 AgentsInitial Therapy CriteriaContinuation Therapy RequirementsProvider Actions and Prior Authorization InstructionsCoding and Submission PathwayDefinitions and ExclusionsStep Therapy RequirementsBackground
    Documentation Required

    Provide clinical diagnosis and prior-therapy evidence; respond to info requests

    Submit clinical documentation confirming a diagnosis of type 2 diabetes and evidence the patient has tried and failed metformin (or metformin combination drugs) or insulin; respond promptly to requests for additional information.

    • Include clinical records that verify a type 2 diabetes diagnosis
    • Include documentation of prior medication trials and failure
    • If Prime Therapeutics requests more information, respond promptly (48 hours for urgent pharmacy requests)
    Denial Risk

    Denial risk for missing type 2 diabetes documentation

    Authorization requests will be denied if the patient is not a type 2 diabetic or if the request lacks clinical documentation supporting a type 2 diabetes diagnosis.

    • Ensure submitted records clearly document the type 2 diabetes diagnosis to avoid denial
    Denial Risk

    Denial for weight-loss indications (excluded agents)

    Requests for GLP-1 medications intended for weight loss (for example, Wegovy, Zepbound, Saxenda) are excluded from coverage and will be denied; patients seeking these agents for weight management will be responsible for out-of-pocket payment.

    • Do not submit prior authorization requests for GLP-1 products when the indication is weight loss or weight management
    • Refer patients to Florida Blue wellness and weight management programs as appropriate